Do J E, Kim Y C
Department of Dermatology, Ajou University School of Medicine, Suwon, Korea.
Clin Exp Dermatol. 2007 Sep;32(5):519-21. doi: 10.1111/j.1365-2230.2007.02451.x. Epub 2007 May 16.
Capecitabine was developed as a prodrug of 5-fluorouracil (FU), with the goal of improving tolerability and intratumour drug concentrations through tumour-specific conversion to the active drug against numerous types of neoplasms. The most frequent adverse cutaneous reaction associated with capecitabine is hand foot syndrome (HFS), presented with symmetrical erythema, dysaesthesia, and desquamation on the palms and soles. Acquired palmoplantar keratoderma (PPK) can occur in various dermatoses associated with metabolic abnormalities, malignancies, and toxic agents. However, there has been no report of PPK after capecitabine chemotherapy. We report two cases of diffuse PPK, which developed in patients with metastatic breast cancer after one cycle of capecitabine chemotherapy. Because oral capecitabine is increasingly used for various solid tumours, clinicians should be aware that keratoderma can develop during capecitabine chemotherapy as a sequential event of HFS.
卡培他滨是作为5-氟尿嘧啶（FU）的前体药物开发的，目的是通过肿瘤特异性转化为活性药物来提高耐受性和肿瘤内药物浓度，以对抗多种类型的肿瘤。与卡培他滨相关的最常见皮肤不良反应是手足综合征（HFS），表现为手掌和足底对称性红斑、感觉异常和脱屑。获得性掌跖角化病（PPK）可发生于与代谢异常、恶性肿瘤和毒性药物相关的各种皮肤病中。然而，尚无卡培他滨化疗后发生PPK的报道。我们报告两例弥漫性PPK，发生于转移性乳腺癌患者接受一个周期卡培他滨化疗后。由于口服卡培他滨越来越多地用于各种实体瘤，临床医生应意识到在卡培他滨化疗期间可能会发生角化病，这是HFS的后续事件。
